The Medicines and Healthcare products Regulatory Agency has authorised a version of the Clenil Modulite inhaler that uses a low-carbon propellant. This change reduces the device's carbon footprint by 90% while keeping the medication identical, offering a more sustainable option for the millions of people who rely on these treatments daily.